Vosilasarm

Last updated
Vosilasarm
RAD140.svg
Clinical data
Other namesRAD140; RAD-140; EP0062; Testolone; Testalone
Routes of
administration 		By mouth [1] [2]
Pharmacokinetic data
Elimination half-life 45–60 hours [2] [3]
Identifiers
  • 2-Chloro-4-{[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino}-3-methylbenzonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C20H16ClN5O2
Molar mass 393.83 g·mol−1
3D model (JSmol)
  • ClC1=C(C#N)C=CC(=C1C)N[C@H]([C@H](C)O)C2=NN=C(O2)C3=CC=C(C=C3)C#N
  • InChI=1S/C20H16ClN5O2/c1-11-16(8-7-15(10-23)17(11)21)24-18(12(2)27)20-26-25-19(28-20)14-5-3-13(9-22)4-6-14/h3-8,12,18,24,27H,1-2H3/t12-,18+/m0/s1
  • Key:XMBUPPIEVAFYHO-KPZWWZAWSA-N

Vosilasarm, also known by the development codes RAD140 and EP0062 and by the black-market name Testolone or Testalone, is a selective androgen receptor modulator (SARM) which is under development for the treatment of hormone-sensitive breast cancer. [4] [5] [6] [7] It is specifically under development for the treatment of androgen receptor-positive, estrogen receptor-negative, HER2-negative advanced breast cancer. [4] [5] [8] Vosilasarm was also previously under development for the treatment of sarcopenia (age-related muscle atrophy), osteoporosis, and weight loss due to cancer cachexia, but development for these indications was discontinued. [4] [9] The drug is taken by mouth. [1] [2]

Contents

Side effects of vosilasarm may include vomiting, dehydration, constipation, decreased appetite, weight loss, changes in sex hormone levels, elevated liver enzymes, and liver toxicity. [2] [10] [11] [12] [13] [14] Vosilasarm is a nonsteroidal SARM, acting as an agonist of the androgen receptor (AR), the biological target of androgens and anabolic steroids like testosterone and dihydrotestosterone (DHT). [15] [7] However, it shows dissociation of effect between tissues in preclinical studies, with agonistic and anabolic effects in muscle, agonistic effects in breast, and partially agonistic or antagonistic effects in the prostate gland and seminal vesicles. [6] [7] [9] [15] [16]

Vosilasarm was developed in 2010 and was first described in the literature in 2011. [15] [9] It was originally developed by Radius Health and is now under development by Ellipses Pharma. [4] [5] The first clinical study of vosilasarm, a small (n=22) phase 1 study in women with metastatic breast cancer, was started in 2017 and completed in 2020, with results published in 2019, 2020, and 2022. [10] [3] [2] [17] [15] As of March 2023, vosilasarm is in phase 1/2 clinical trials for the treatment of breast cancer. [4] [18]

Aside from its development as a potential pharmaceutical drug, vosilasarm is on the World Anti-Doping Agency list of prohibited substances [19] and is sold for physique- and performance-enhancing purposes by black-market Internet suppliers. [6] [1] Vosilasarm is often used in these contexts at doses that have not been evaluated in clinical trials, with unknown effectiveness and safety. [6] [1] Many products sold online that are purported to be a specific SARM either contain none or contain other unrelated substances. [6] [20] Social media has played an important role in facilitating the widespread non-medical use of SARMs. [21]

Medical uses

Vosilasarm is not approved for any medical use and is not available as a licensed pharmaceutical drug as of 2023. [4]

Side effects

Side effects of vosilasarm in preliminary clinical studies in women with metastatic breast cancer have included vomiting (27%), dehydration (27%), constipation, decreased appetite and weight loss (27%), hypophosphatemia, decreased sex hormone-binding globulin (SHBG) levels (100%), increased prostate-specific antigen (PSA) levels (80%), and abnormal liver function tests, including elevated aspartate aminotransferase (59%), elevated alanine aminotransferase (46%), and elevated total blood bilirubin (27%). [2] [10]

In gonadally intact male cynomolgus monkeys, vosilasarm suppressed testosterone levels by around 50% (from ~600–800 ng/dL to ~200–300 ng/dL) across three dose levels (0.01 mg/kg, 0.1 mg/kg, and 1.0 mg/kg). [6] [9] Changes in serum lipids, including of triglycerides, LDL cholesterol, and HDL cholesterol were also observed. [6] [7] [9] Elevated liver enzymes were minimally observed in monkeys. [6] [7] [9]

A number of case reports of liver toxicity with non-medical use of vosilasarm have been published. [11] [12] [13] [14] A case report of acute myocarditis with non-medical use of vosilasarm also exists. [1] [22]

Overdose

Vosilasarm has been assessed in clinical trials in women with breast cancer at doses ranging from 50 to 150 mg/day, with the maximum safe and tolerated dose being 100 mg/day. [10] [3] [2] The drug sold via black-market Internet suppliers and used non-medically has been reported to be taken at doses of 5 to 30 mg/day, with unknown adverse effects and risks. [1] [23]

Pharmacology

Pharmacodynamics

Vosilasarm is selective androgen receptor modulator (SARM), or a tissue-selective mixed agonist or partial agonist of the androgen receptor (AR). [6] [7] This receptor is the biological target of endogenous androgens like testosterone and dihydrotestosterone (DHT) and of synthetic anabolic steroids like nandrolone and oxandrolone. [24] [25] [26] [27] Vosilasarm shows high affinity for the AR, with a Ki value of 7 nM (relative to 29 nM for testosterone and 10 nM for DHT). [6] [7] [9] It shows good selectivity for the AR over other steroid hormone receptors, with the closest off-target receptor being the progesterone receptor (IC50 = 750 nM versus 0.2 nM for progesterone). [9] Vosilasarm also shows potent efficacy in terms of AR activation, with an EC50 value of 0.1 nM in the C2C12 osteoblast differentiation assay. [7] [9] The AR is widely expressed in tissues throughout the body, including in the prostate gland, seminal vesicles, genitals, gonads, skin, hair follicles, muscle, bone, heart, adrenal cortex, liver, kidneys, and brain, among others. [26] [27] Vosilasarm has been found to have varying full agonist and partial agonist AR-mediated effects in different tissues, including potent agonistic and anabolic activity in muscle and bone, potent agonistic effects in AR-expressing human breast cancer cell lines, and partial agonist or antagonist activity in the prostate gland and seminal vesicles. [6] [7] [9] [15] [16]

In castrated immature male rats, vosilasarm (at 10 mg/kg/day orally, the highest assessed dose) maximally stimulated prostate weight to 67%, seminal vesicle weight to 59%, and levator ani muscle weight to 117% compared to that induced with testosterone propionate 1 mg/kg/day. [7] [6] [9] Moreover, when combined with testosterone propionate, vosilasarm partially antagonized the weight increases of the prostate gland and seminal vesicles, reducing them to 84% and 78% (both from 100%), respectively. [7] [9] Conversely however, the combination of testosterone propionate and vosilasarm was additive in terms of levator ani muscle weight stimulation, increasing it to 124%. [7] [9] Vosilasarm was found to stimulate muscle at a dose much lower than that required to stimulate the prostate. [7] A dose of 0.3 mg/kg/day stimulated levator ani muscle weight to a similar extent relative to the levator ani weight in non-castrated controls. [7] [9] Conversely, a 33-fold higher dose of 10 mg/kg/day was required to stimulate prostate weight to a similar extent as that in non-castrated controls. [9] Similarly, in gonadally intact immature rats, 0.3 mg/kg/day vosilasarm stimulated levator ani muscle weight to a similar extent as testosterone propionate 0.5 mg/kg/day, but a dose of 30 mg/kg/day (100-fold higher) was required to stimulate the prostate to a similar extent as testosterone propionate 0.5 mg/kg/day. [7] [6] [9] Hence, in rats, vosilasarm is a potent full agonist of the levator ani muscle but a partial agonist and antagonist of the prostate and seminal vesicles, and is strongly selective for stimulating the levator ani muscle over the prostate gland. [7] [9] In young male cynomolgus monkeys, vosilasarm, at oral doses of 0.01 mg/kg/day, 0.1 mg/kg/day, and 1 mg/kg/day for 28 days, dose-dependently stimulated body weight (+10% at ≥0.1 mg/kg/day) and numerically increased lean body mass. [7] [6] [15] [9] The lack of statistical significance was likely due to the small sample sizes per dosing group (n=3 each). [15] [9] No data on vosilasarm and lean body mass in humans have been published as of 2022. [2] [15]

Pharmacokinetics

Vosilasarm shows good oral bioavailability in rats (27–63%) and monkeys (65–75%) [9] and is orally active in humans. [1] [2] The elimination half-life of vosilasarm is 45 to 60 hours. [2] [3]

Chemistry

Vosilasarm is an oxadiazole aniline derivative. [7] Other aniline SARMs include AC-262536 and ACP-105. [7]

History

Vosilasarm was developed by Radius Health in 2010. [15] [9] It was first described in in the literature in 2011 in a paper detailing its design, synthesis, and preclinical characterization in vitro and in rats and monkeys. [9] It was stated in this paper that phase 1 clinical studies of vosilasarm for treatment of severe weight loss due to cancer cachexia were being prepared. [9] [7] However, these studies were never completed or published and development for this indication was discontinued. [4] Subsequently, vosilasarm was repurposed for the treatment of breast cancer. [4]

Society and culture

Names

Vosilasarm is the generic name of the drug and its International Nonproprietary Name (INN). [28] It is also known by its pharmaceutical developmental code names RAD140 (Radius Health) and EP0062 (Ellipses Pharma). [4] Additionally, vosilasarm is known by the black-market name Testolone or Testalone. [15] [6] [23]

Non-medical use

Vosilasarm and other SARMs are sold by black-market vendors on the Internet. [6] [20] Aside from vosilasarm, the other most commonly used SARMs include enobosarm (ostarine; GTx-024, S-22), LGD-4033 (VK5211; "ligandrol"), and andarine (GTx-007; S-4). [21] Social media has played an important role in facilitating the widespread non-medical use of SARMs. [21]

Research

The first-in-human study, a phase 1 trial, was initiated in October 2017 and completed in September 2020 in postmenopausal women with breast cancer. [10] [3] [2] [17] [15] The study investigated oral doses of vosilasarm of 50 mg/day to 150 mg/day, with the maximum tolerated dose found to be 100 mg/day. [10] [3] [2] A phase 1/2 study proposal of vosilasarm for treatment of breast cancer was published in 2023. [18] It will recruit up to 128 patients. [18]

Related Research Articles

<span class="mw-page-title-main">Methyltestosterone</span> Chemical compound

Methyltestosterone, sold under the brand names Android, Metandren, and Testred among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, at low doses as a component of menopausal hormone therapy for menopausal symptoms like hot flashes, osteoporosis, and low sexual desire in women, and to treat breast cancer in women. It is taken by mouth or held in the cheek or under the tongue.

<span class="mw-page-title-main">Nandrolone decanoate</span> Anabolic steroid

Nandrolone decanoate, sold under the brand name ROLON among others, is an androgen and anabolic steroid (AAS) medication which is used primarily in the treatment of anemias and wasting syndromes, as well as osteoporosis in menopausal women. It is given by injection into muscle or fat once every one to four weeks.

<span class="mw-page-title-main">Selective androgen receptor modulator</span> Class of pharmaceutical drugs

Selective androgen receptor modulators (SARMs) are a class of drugs that selectively activate the androgen receptor in specific tissues, promoting muscle and bone growth while having less effect on male reproductive tissues like the prostate gland.

<span class="mw-page-title-main">Desoxymethyltestosterone</span> Chemical compound

Desoxymethyltestosterone (DMT), known by the nicknames Madol and Pheraplex, is a synthetic and orally active anabolic–androgenic steroid (AAS) and a 17α-methylated derivative of dihydrotestosterone (DHT) which was never marketed for medical use. It was one of the first designer steroids to be marketed as a performance-enhancing drug to athletes and bodybuilders.

<span class="mw-page-title-main">Anabolic steroid</span> Steroidal androgen that is structurally related and has similar effects to testosterone

Anabolic steroids, also known as anabolic-androgenic steroids (AAS), are a class of drugs that are structurally related to testosterone, the main male sex hormone, and produce effects by binding to the androgen receptor. Anabolic steroids have a number of medical uses, but are also used by athletes to increase muscle size, strength, and performance.

<span class="mw-page-title-main">BMS-564,929</span> Chemical compound

BMS-564,929 is an investigational selective androgen receptor modulator (SARM) which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men ("andropause"). These symptoms may include depression, loss of muscle mass and strength, reduction in libido and osteoporosis. Treatment with exogenous testosterone is effective in counteracting these symptoms but is associated with a range of side effects, the most serious of which is enlargement of the prostate gland, which can lead to benign prostatic hypertrophy and even prostate cancer. This means there is a clinical need for selective androgen receptor modulators, which produce anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in the prostate.

<span class="mw-page-title-main">S-40503</span> Chemical compound

S-40503 is an investigational selective androgen receptor modulator (SARM) developed by the Japanese company Kaken Pharmaceuticals, which was developed for the treatment of osteoporosis. SARMs are a new class of drugs which produce tissue-specific anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in other tissues such as in the prostate gland, thus avoiding side effects such as benign prostatic hypertrophy which can occur following treatment with unselective androgens like testosterone or anabolic steroids.

<span class="mw-page-title-main">LGD-2226</span> Chemical compound

LGD-2226 is an investigational selective androgen receptor modulator (SARM), which is being developed for treatment of muscle wasting and osteoporosis.

<span class="mw-page-title-main">Enobosarm</span> Investigational selective androgen receptor modulator

Enobosarm, also formerly known as ostarine and by the developmental code names GTx-024, MK-2866, and S-22, is a selective androgen receptor modulator (SARM) which is under development for the treatment of androgen receptor-positive breast cancer in women and for improvement of body composition in people taking GLP-1 receptor agonists like semaglutide. It was also under development for a variety of other indications, including treatment of cachexia, Duchenne muscular dystrophy, muscle atrophy or sarcopenia, and stress urinary incontinence, but development for all other uses has been discontinued. Enobosarm was evaluated for the treatment of muscle wasting related to cancer in late-stage clinical trials, and the drug improved lean body mass in these trials, but it was not effective in improving muscle strength. As a result, enobosarm was not approved and development for this use was terminated. Enobosarm is taken by mouth.

<span class="mw-page-title-main">Andarine</span> Chemical compound

Andarine is a selective androgen receptor modulator (SARM) which was developed by GTX, Inc for the treatment of conditions such as muscle wasting, osteoporosis, and benign prostatic hypertrophy (BPH), using the nonsteroidal antiandrogen bicalutamide as a lead compound. Development of andarine for all indications has been discontinued, in favor of the structurally related and improved compound enobosarm.

<span class="mw-page-title-main">1-Testosterone</span> Chemical compound

1-Testosterone, also known as δ1-dihydrotestosterone (δ1-DHT), as well as dihydroboldenone, is a synthetic anabolic–androgenic steroid (AAS) and a 5α-reduced derivative of boldenone (Δ1-testosterone). It differs from testosterone by having a 1(2)-double bond instead of a 4(5)-double bond in its A ring. It was legally sold online in the United States until 2005, when it was reclassified as a Schedule III drug.

<span class="mw-page-title-main">Bolandione</span> Chemical compound

Bolandione, also known as 19-norandrostenedione, as well as 19-norandrost-4-en-3,17-dione or estr-4-ene-3,17-dione, is a precursor of the anabolic-androgenic steroid (AAS) nandrolone (19-nortestosterone). Until 2005, bolandione was available without prescription in United States, where it was marketed as a prohormone, but it is now classified as a Schedule III drug. It is also banned from use in many sports, including the Olympic Games, under the World Anti-Doping Code. Bolandione is readily metabolized to nandrolone after oral administration, but its potency to transactivate the androgen receptor dependent reporter gene expression is 10 times lower as compared to dihydrotestosterone (DHT).

<span class="mw-page-title-main">AC-262,536</span> Chemical compound

AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5 nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the levator ani muscle weight increase of testosterone, but only around 27% of its maximal effect on prostate gland weight. It is an aniline SARM related to ACP-105 and vosilasarm (RAD140).

<span class="mw-page-title-main">Ligandrol</span> Chemical compound

Ligandrol, also known by the developmental code names VK5211 and LGD-4033, is a selective androgen receptor modulator (SARM) which is under development for the treatment of muscle atrophy in people with hip fracture. It was also under development for the treatment of cachexia, hypogonadism, and osteoporosis, but development for these indications was discontinued. Ligandrol has been reported to dose-dependently improve lean body mass and muscle strength in preliminary clinical trials, but is still being developed and has not been approved for medical use. The drug is taken by mouth.

<span class="mw-page-title-main">Nandrolone phenylpropionate</span> Anabolic steroid

Nandrolone phenylpropionate (NPP), or nandrolone phenpropionate, sold under the brand name Durabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used primarily in the treatment of breast cancer and osteoporosis in women. It is given by injection into muscle once every week. Although it was widely used in the past, the drug has mostly been discontinued and hence is now mostly no longer available.

<span class="mw-page-title-main">TFM-4AS-1</span> Dual selective androgen receptor modulator

TFM-4AS-1 is a dual selective androgen receptor modulator (SARM) and 5α-reductase inhibitor. It is a potent and selective partial agonist (Emax = 55%) of the androgen receptor (IC50 = 30 nM) and inhibitor of 5α-reductase types I and II (IC50 = 2 and 3 nM, respectively). TFM-4AS-1 shows tissue-selective androgenic effects; it promotes the accumulation of bone and muscle mass and has reduced effects in reproductive tissues and sebaceous glands. In an animal study, TFM-4AS-1 stimulated sebaceous gland formation only 31% as much as dihydrotestosterone (DHT) at doses that were as anabolic or more so than DHT. In addition, TFM-4AS-1 only weakly promoted growth of the prostate gland and it partially antagonized the actions of DHT in the seminal vesicles and endogenous androgens in the prostate gland. Structurally, TFM-4AS-1 is a 4-azasteroid. A structurally related and more advanced version of TFM-4AS-1, MK-0773, was developed and pursued for potential pharmaceutical use.

<span class="mw-page-title-main">MK-0773</span> Chemical compound

MK-0773, also known as PF-05314882, is a steroidal, orally active selective androgen receptor modulator (SARM) that was under development by Merck and GTx for the treatment of sarcopenia in women and men. Clinical trials for sarcopenia began in late 2007 but the collaboration between Merck and GTx ended in early 2010 and GTx terminated development of MK-0773 shortly thereafter. MK-0773 was developed as a more advanced version of the related compound TFM-4AS-1.

<span class="mw-page-title-main">Pharmacology of bicalutamide</span>

The pharmacology of bicalutamide is the study of the pharmacodynamic and pharmacokinetic properties of the nonsteroidal antiandrogen (NSAA) bicalutamide. In terms of pharmacodynamics, bicalutamide acts as a selective antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has no capacity to activate the AR. It does not decrease androgen levels and has no other important hormonal activity. The medication has progonadotropic effects due to its AR antagonist activity and can increase androgen, estrogen, and neurosteroid production and levels. This results in a variety of differences of bicalutamide monotherapy compared to surgical and medical castration, such as indirect estrogenic effects and associated benefits like preservation of sexual function and drawbacks like gynecomastia. Bicalutamide can paradoxically stimulate late-stage prostate cancer due to accumulated mutations in the cancer. When used as a monotherapy, bicalutamide can induce breast development in males due to its estrogenic effects. Unlike other kinds of antiandrogens, it may have less adverse effect on the testes and fertility.

<span class="mw-page-title-main">ACP-105</span> Chemical compound

ACP-105 is a drug which acts as a selective androgen receptor modulator (SARM). It has been investigated for potential use in the treatment of age-related cognitive decline. The drug has been found to reduce anxiety-like behavior in a mouse model of Alzheimer's disease when administered alone, as well as enhance spatial memory when coadministered with the selective estrogen receptor β agonist AC-186. ACP-105 is an aniline SARM and is related to AC-262536 and vosilasarm (RAD140).

References

  1. 1 2 3 4 5 6 7 Hall E, Vrolijk MF (July 2023). "Androgen Receptor and Cardiovascular Disease: A Potential Risk for the Abuse of Supplements Containing Selective Androgen Receptor Modulators". Nutrients. 15 (15): 3330. doi: 10.3390/nu15153330 . PMC   10420890 . PMID   37571268.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 LoRusso P, Hamilton E, Ma C, Vidula N, Bagley RG, Troy S, et al. (January 2022). "A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer". Clinical Breast Cancer. 22 (1): 67–77. doi:10.1016/j.clbc.2021.08.003. PMID   34565686. S2CID   237943992.
  3. 1 2 3 4 5 6 Hamilton E, LoRusso P, Ma C, Vidula N, Bagley RG, Troy S, et al. (2020-02-15). "Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER ), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer". Cancer Research. 80 (4 Supplement): P5–11–01. doi:10.1158/1538-7445.sabcs19-p5-11-01. S2CID   216326672.
  4. 1 2 3 4 5 6 7 8 9 "Vosilasarm - Ellipses Pharma". AdisInsight. Springer Nature Switzerland AG.
  5. 1 2 3 "Our Portfolio | Ellipses Pharma". Ellipses Life. Retrieved 11 October 2023.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Machek SB, Cardaci TD, Wilburn DT, Willoughby DS (December 2020). "Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review". Steroids. 164: 108753. doi:10.1016/j.steroids.2020.108753. PMID   33148520. S2CID   225049089.
  7. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Zhang X, Sui Z (February 2013). "Deciphering the selective androgen receptor modulators paradigm". Expert Opinion on Drug Discovery. 8 (2): 191–218. doi:10.1517/17460441.2013.741582. PMID   23231475. S2CID   2584722.
  8. ↑ Clinical trial number NCT05573126 for "Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer" at ClinicalTrials.gov
  9. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Miller CP, Shomali M, Lyttle CR, O'Dea LS, Herendeen H, Gallacher K, et al. (February 2011). "Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140". ACS Medicinal Chemistry Letters. 2 (2): 124–129. doi:10.1021/ml1002508. PMC   4018048 . PMID   24900290.
  10. 1 2 3 4 5 6 Hamilton E, Vidula N, Ma C, LoRusso P, Bagley RG, Yu Z, et al. (2019). "Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC)". Annals of Oncology. 30: v123. doi: 10.1093/annonc/mdz242.038 .
  11. 1 2 Vignali JD, Pak KC, Beverley HR, DeLuca JP, Downs JW, Kress AT, et al. (May 2023). "Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users". Journal of Xenobiotics. 13 (2): 218–236. doi: 10.3390/jox13020017 . PMC   10204391 . PMID   37218811.
  12. 1 2 Flores JE, Chitturi S, Walker S (March 2020). "Drug-Induced Liver Injury by Selective Androgenic Receptor Modulators". Hepatology Communications. 4 (3): 450–452. doi: 10.1002/hep4.1456 . PMC   7049679 . PMID   32140660.
  13. 1 2 Mohideen H, Hussain H, Dahiya DS, Wehbe H (February 2023). "Selective Androgen Receptor Modulators: An Emerging Liver Toxin". Journal of Clinical and Translational Hepatology. 11 (1): 188–196. PMC   9647117 . PMID   36479151.
  14. 1 2 Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A (December 2023). "Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases". European Journal of Clinical Pharmacology. 80 (2): 185–202. doi: 10.1007/s00228-023-03592-3 . PMC   10847181 . PMID   38059982.
  15. 1 2 3 4 5 6 7 8 9 10 11 Fonseca GW, Dworatzek E, Ebner N, Von Haehling S (August 2020). "Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials". Expert Opinion on Investigational Drugs. 29 (8): 881–891. doi:10.1080/13543784.2020.1777275. PMID   32476495. S2CID   219174372.
  16. 1 2 Yu Z, He S, Wang D, Patel HK, Miller CP, Brown JL, et al. (December 2017). "Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action". Clinical Cancer Research. 23 (24): 7608–7620. doi: 10.1158/1078-0432.CCR-17-0670 . PMID   28974548.
  17. 1 2 Clinical trial number NCT03088527 for "Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer" at ClinicalTrials.gov
  18. 1 2 3 Lim E, Hamilton E, Palmieri C, Arkenau HT, Brook S, Fisher G, et al. (1 March 2023). "Abstract OT1-02-02: A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer". Cancer Research. 83 (5_Supplement): OT1–02–02-OT1-02-02. doi:10.1158/1538-7445.SABCS22-OT1-02-02. ISSN   1538-7445. S2CID   257320030.
  19. ↑ "The Prohibited List".
  20. 1 2 Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D (November 2017). "Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet". JAMA. 318 (20): 2004–2010. doi:10.1001/jama.2017.17069. PMC   5820696 . PMID   29183075.
  21. 1 2 3 Hahamyan HA, Vasireddi N, Voos JE, Calcei JG (August 2023). "Social media's impact on widespread SARMs abuse". The Physician and Sportsmedicine. 51 (4): 291–293. doi: 10.1080/00913847.2022.2078679 . PMID   35574698.
  22. ↑ Padappayil RP, Chandini Arjun A, Vivar Acosta J, Ghali W, Mughal MS (January 2022). "Acute Myocarditis From the Use of Selective Androgen Receptor Modulator (SARM) RAD-140 (Testolone)". Cureus. 14 (1): e21663. doi: 10.7759/cureus.21663 . PMC   8881971 . PMID   35233331.
  23. 1 2 Burmeister MA, Fincher TK, Graham WH (2020). "Recreational use of selective androgen receptor modulators". US Pharm. 45 (60): 15–18.
  24. ↑ Handelsman DJ (5 October 2020). "Androgen Physiology, Pharmacology, Use and Misuse". In Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. (eds.). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. PMID   25905231.
  25. ↑ Wu C, Kovac JR (October 2016). "Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health". Current Urology Reports. 17 (10): 72. doi:10.1007/s11934-016-0629-8. PMID   27535042. S2CID   43199715.
  26. 1 2 Mohler ML, Nair VA, Hwang DJ, Rakov IM, Patil R, Miller DD (2005-10-28). "Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates". Expert Opinion on Therapeutic Patents. Informa Healthcare. 15 (11): 1565–1585. doi:10.1517/13543776.15.11.1565. ISSN   1354-3776. S2CID   96279138.
  27. 1 2 Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi:10.1038/bjp.2008.165. PMC   2439524 . PMID   18500378.
  28. ↑ "Recommended INN: List 84 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (3). 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.